Vaccine maker Biological E (BE) on Thursday said it has secured World Health Organisation (WHO) pre-qualification for its new 14-valent pneumococcal conjugate vaccine, a regulatory milestone that paves the way for broader global distribution of the shot designed for infants.

The WHO prequalification allows the PNEUBEVAX 14 (BE-PCV-14) vaccine to be procured by United Nations agencies and global immunisation initiatives. This marks the 11th vaccine from the Hyderabad-based vaccine maker’s portfolio to achieve WHO pre-qualification status.

The vaccine is designed to protect infants from six weeks of age against invasive diseases, including pneumonia, meningitis, and sepsis. The formulation covers 14 Streptococcus pneumoniae serotypes, notably including strains 22F and 33F, which are not co

See Full Page